Posted in News
As has been widely reported in the press, adalimumab is now available in a range of biosimilar products and NHSE has issued guidance on the use of the new biosimilars. Products from Amgen (Amgevita®), Mylan (Hulio®), Biogen (Imraldi®) and Sandoz (Hyrimoz®) as well as the original Abbvie product (Humira®) are currently being issued.
In order for these products to be accurately mapped at AMP (actual medicinal product) level, Trusts are asked to include either the brand name or the manufacturer of each adalimumab biosimilar used. Rx-info will not assume that a description for adalimumab without a brand name or manufacturer implies that the originator product has been issued.
Reports have been added to both Define and Refine (under the Biosimilar and Model Hospital sections) to monitor the use of originator and biosimilar.